Prognostic markers inprostate cancer

Expert Review of Molecular Diagnostics

Volumn 2, Issue 2, 2002, Pages 129-142

  Ross, Jeffrey s ^a,b   Sheehan, Christine e ^b   Fisher, Hugh ag ^b   Kauffman, Ronald a ^b   Dolen, Eric m ^b   Kallakury, Bhaskar vs ^c  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; biomarker; cell adhesion; cell proliferation; DNA ploidy; grade; HER 2 neu; oncogene; prognosis; prostate cancer; proteasome; stage

Indexed keywords

CELL ADHESION MOLECULE; GROWTH PROMOTOR; TUMOR MARKER; ANDROGEN RECEPTOR; GROWTH FACTOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27;

APOPTOSIS; CANCER STAGING; CELL CYCLE; GENETICS; HUMAN; MALE; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW; VASCULARIZATION; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL PRACTICE; CYTOGENETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC MARKER; HISTOPATHOLOGY; MICROSATELLITE INSTABILITY; MORPHOMETRICS; NEEDLE BIOPSY; ONCOGENE NEU; PLOIDY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN DEGRADATION; TUMOR VOLUME; VALIDATION PROCESS;

APOPTOSIS; CELL ADHESION MOLECULES; CELL CYCLE; GROWTH SUBSTANCES; HUMANS; MALE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; HUMAN;

EID: 0035998291     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2.2.129     Document Type: Review

References (159)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1991. CA Cancer J. Clin. 41, 19– 36 (1991).
2. Seidman H, Mushinski MH, Geib SK et al. Probabilities of eventually developing or dying of cancer United States, 1985. CA Cancer J. Clin. 35, 36– 56 (1985).
3. Mettlin CJ, Murphy GP, Ho R et al. The national cancer database report on longitudinal observations on prostate cancer. Cancer 77, 2162–2166 (1996).
4. Lu-Yao GL, Greenberg R. Changes in prostate cancer incidence and treatment in USA. Lancet 343, 251–254 (1994).
5. Cookson MS. Prostate cancer: screening and early detection. Cancer Control 8, 133–140 (2001).
6. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11, 167–170 (2000).
7. Montironi R, Mazzucchelli R, Marshall J.R., Christiano AP, Yoshida BA, Dubauskas Z et al. Development of markers of prostate cancer metastasis. Review and perspective. Urol. Oncol. 5, 217–223 (2000).
8. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J. Clin. 49, 282–296 (1999).
9. Bostwick DG, Grignon DJ, Hammond ME et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 995–1000 (2000).
10. Harding MA, Theodorescu D. Prostate tumor progression and prognosis. interplay of tumor and host factors. Urol. Oncol. 5, 258–264 (2000).
11. Alers JC, Rochat J, Krijtenburg PJ et al. Identification of genetic markers for prostatic cancer progression. Lab. Invest. 80, 931–942 (2000).
12. Amanatullah DF, Reutens AT, Zafonte BT et al. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front. Biosci. ApR1 5, D372–390 (2000).
13. Ohori M, Wheeler TM, Scardino PT. The New American Joint committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 74, 104–114 (1994).
14. Hammond ME, Fitzgibbons PL, Compton CC et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors which, how and so what? Arch. Pathol. Lab. Med. 124, 958–965 (2000).
15. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Tumors of the prostate gland, seminal vesicles, male urethra and penis. In: Atlas of Tumor Pathology (Third Series). Armed Forces Institute of Pathology, Washington, DC, USA, 217–254 (2000).
16. D.F., Gleason, Histologic grading and clinical staging of prostatic carcinoma, In: Urologic Pathology, The Prostate., Tannenbaum M (Ed.), Lea and Febiger, Philadelphia, PA, USA, 171, (1977)
17. Koch MO, Foster RS, Bell B et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J. Urol. 164 (3 Pt 1), 749–753 (2000).
18. McNeal JE, Villers AA, Redwine EA et al. Histologic differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66, 1225–1233 (1990).
19. McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum. Pathol. 23, 258–266 (1992).
20. Stamey TA, Freiha FS, McNeal JE et al. Localized prostate cancer. Cancer 71, 933–938 (1993).
21. Ravery V, Chastang C, Toublanc M et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1–T2 prostate cancer. Eur. Urol. 37, 449–455 (2000).
22. Montie JE. Staging of prostate cancer. Cancer 75, 1814–1818 (1995).
23. Robinette MA, Robson CJ, Farrow GA et al. Giant serial step sections of the prostate in assessment of the accuracy of clinical staging in patients with localized prostatic carcinoma J. Urol. 133(Suppl.), 242A (1984).
24. Ohori AM, Scardino PT, Lapin SL et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am. J. Surg. Pathol. 17, 1252–1261 (1993).
25. Cheng L, Darson MF, Bergstralh EJ et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 86, 1775–1782 (1999).
26. Humphrey PA, Frazier HA, Vollmer RT et al. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostatespecific antigen levels. Cancer 71, 121–127 (1993).
27. Epstein JI, Partin AW, Sauvageot J et al. Prediction of progression following radical prostatectomy. Am. J. Surg. Pathol. 20, 286–292 (1996).
28. Herman CM, Wilcox GE, Kattan MW et al. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am. J. Surg. Pathol. 24, 859–863 (2000).
29. Fowler J, Jr., Whitmore WF. The incidence and extent of pelvic lymph node metastasis in apparently localized prostatic cancer. Cancer 47, 2941–2949 (1981).
30. Potter SR, Mangold LA, Shue MJ et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 89, 2577–2586 (2000).
31. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. Urology 163, 1183–1188 (2000).
32. Foster CS, Abel PD. Clinical and molecular techniques for diagnosis and monitoring of prostate cancer. Hum. Pathol. 23, 395–401 (1992).
33. Isaacs JT. Molecular markers for prostate cancer metastasis. Am. J. Pathol. 150, 1511–1521 (1997).
34. Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J. Cell. Physiol. 189, 245–256 (2001).
35. Murphy GP, Barren RJ, Erickson SJ et al. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer 78, 809–818 (1996).
36. Stege R, Grande M, Carlstrom K et al. Prognostic significance of tissue prostatespecific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 6, 160–165 (2000).
37. Chang SS, Reuter VE, Heston WD et al. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumorassociated neovasculature. Cancer Res. 59, 3192–3198 (1999).
38. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735–1740 (1998).
39. Gu Z, Thomas G, Yamashiro J et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288–1296 (2000).
40. Wieacker PF, Knoke I, Jakubiczka S. Clinical and molecular aspects of androgen receptor defects. Exp. Clin. Endocrinol. Diabetes 106, 446–453 (1998).
41. Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 195, 138–146 (2001).
42. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgenrefractory prostate cancer. J. Natl Cancer Inst. 93 (22), 1687–1697 (2001).
43. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152, 1–9 (1998).
44. Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc. Natl Acad. Sci. USA 89, 6319–6323 (1992).
45. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer 71, 2574–2580 (1993).
46. Collembell M, Symmans F, Gil S et al. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390–400 (1993).
47. Goel A, Abou-Ellela A, DeRose PB et al. The prognostic significance of proliferation in prostate cancer. J. Urol. Pathol. 4, 213–223 (1996).
48. Scalzo DA, Kallakury BVS, Gaddipati RV et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts post radiation recurrence of prostatic adenocarcinomas. Am. J. Clin. Pathol. 109, 163–168 (1998).
49. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (pcna) immunohistochemistry as a prognostic factor in prostatic carcinoma. J. Pathol. 168, 7–13 (1992).
50. Sadasivan R, Morgan R, Jennings S et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150, 126–131 (1993).
51. Henke RP, Kruger E, Ayhan N et al. Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. Virc Arch. Path. Anat. Histopathol. 422, 61–66 (1993).
52. Furuya K, Akahura K, Masai M et al. Changes in cell proliferation and apoptosis during local progression of prostate cancer. Anticancer Res. 20, 1135–1139 (2000).
53. Cheng L, Pisansky TM, Sebo TJ et al. Cell proliferationz in prostate cancer patients with lymph node metastasis: a marker for progression. Clin. Cancer Res. 5, 2820–2823 (1999).
54. Drobnjak M, Osman I, Scher HI et al. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res. 6, 1891–1895 (2000).
55. Kuczyk MA, Bokemeyer C, Hartmann J et al. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol. Rep. 8, 1401–1407 (2001).
56. Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAFI) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 49, 191–199 (2001).
57. Yang RM, Naitoh J, Murphy M et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159, 941–945 (1998).
58. Kuczyk M, Hradil K, Schubach J et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br. J. Cancer 81, 1052–1058 (1999).
59. Halvorsen OJ, Hostmark J, Haukaas S et al. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88, 416–424 (2000).
60. Kallakury BVS, Sheehan CE, Ambros RA et al. Prognostic significance of p34cdc2 and cyclin D1 protein expression in prostatic adenocarcinomas. Cancer 80, 753–763 (1997).
61. Ross JS, Nazeer T, Church K et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72, 3020–3028 (1993).
62. Winkler HC, Rainwater LM, Myers RP et al. Stage D1 prostatic carcinoma: significance of DNA ploidy patterns studied by flow cytometry. Mayo Clin. Proc. 63, 103–112 (1988).
63. Peters AJM, Miles BJ, Kubus JJ et al. The prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. Anal. Quant. Cytol. Histol. 12, 359–365 (1990).
64. Peters-Gee JM, Miles BJ, Cerny JC et al. Prognostic significance of DNA quantification in stage D1 prostatic carcinoma with the use of image analysis. Cancer 70, 1159–1165 (1992).
65. Foster CH, McLoughlin J, Bashir I et al. Markers of the metastatic phenotype in prostate cancer. Hum. Pathol. 23, 381–394 (1992).
66. Montgomery BT, Nativ O, Blute M et al. Stage B prostate adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Arch. Surg. 125, 327–331 (1990).
67. Ross JS, Figge H, Bui HX et al. Prediction of pathologic stage and post prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 74, 2811–2818 (1994).
68. Ross JS, Sheehan CE, Ambros RA et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am. J. Surg. Pathol. 23, 296–301 (1999).
69. D.A., Brinker, J.S., Ross, T.A., Tran, et al., Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy and grade?, JUrol, (1999), 162, 2036-2039
70. Macouska JA, Trybus TM, Wojno KJ. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 55, 776–782 (2000).
71. Dong JT, Chen C, Stultz BG et al. Deletion of 13q21 is associated with aggressive prostate cancers. Cancer Res. 60, 3880–3883 (2000).
72. Bowen C, Rubendorf L, Voeller HJ et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60, 6111–6115 (2000).
73. Cadeddu JA, Pearson JD, Partin AW et al. Relationship between changes in prostatespecific antigen and prognosis of prostate cancer. Urology 42, 383–389 (1993).
74. Mohler JL, Metts JC, Zhang X-Z et al. Nuclear morphometry in automatic biopsy and radical prostatectomy specimens of prostatic carcinoma. Anal. Quant. Cytol. Histol. 16, 415–420 (1994).
75. Mohler JL, Partin AW, Epstein JI et al. Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer 69, 511–519 (1992).
76. Hurwitz MD, DeWeese TI, Zinreich ES et al. Nuclear morphometry predicts disease-free survival for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. Int. J. Cancer 22, 594–597 (1999).
77. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401–409 (1993).
78. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum. Pathol. 24, 220–226 (1993).
79. Siegal JA, Enyou YU, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 75, 2545–2551 (1995).
80. Silberman MA, Partin AW, Veltri R.W., Brawer MK, Deering RE, Brown M et al. Predictors of pathologic stage in prostatic carcinoma. Cancer 73, 678–687 (1994).
81. Strohmeyer D, Rossing C, Strauss F et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42, 26–33 (2000).
82. De la Taille A, Katz AE, Bagiella E et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. Am. J. Clin. Pathol. 113, 555–562 (2000).
83. Gettman MT, Bergstrahl EJ, Blute M. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density. Urology 51, 79–85 (1998).
84. Jackson MW, Roberts JS, Heckford SE et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62, 854–859 (2002).
85. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results and potential applications of color Doppler US scanning. Radiology 186, 509–513 (1993).
86. Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color doppler sonography with histologic correlation of each biopsy site. Radiology 195, 86–90 (1995).
87. Mohamed I, Peterson RO, Alexander AA et al. Color doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 50, 906–912 (1997).
88. Louvar E, Littrup PJ, Goldstein A et al. Correlation of color doppler flow in the prostate with tissue microvascularity. Cancer 83, 135–140 (1998).
89. Partin AW, Getzenberg RH, Carmichael MJ et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53, 744–746 (1993).
90. Wise GJ, Marella VK, Talluri G et al. Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 164, 722–725 (2000).
91. Nakashima J, Machibana M, Horiguchi Y et al. Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6, 2702–2706 (2000).
92. Ware JL. Prostate cancer progression. Implications of Histopathology. Am. J. Pathol. 145, 983–993 (1994).
93. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-1 and prostate cancer. Scand. J. Urol. Nephrol 34, 85–94 (2000).
94. Borre M, Newstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res. 6, 1882–1890 (2000).
95. Kuniyasu H, Troncoso P, Johnson D et al. Relative expression of Type IV collagenase, E-cadherin and vascular endothelial growth factor/vascular permieability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res. 6, 2295–2308 (2000).
96. Bussemakers MJ, van-Moorselaar R.J., Giroldi LA et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 52, 2916–2922 (1992).
97. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer Metastasis Rev. 12, 29–37 (1993).
98. Umbas R, Schalken JA, Aalders TW et al. Expression of the cellular adhesion molecule e-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52, 5104–5109 (1992).
99. Bussemakers MJ, van Bokhoven A, Tomita K et al. Complex cadherin expression in human prostate cancer cells. Int. J. Cancer 85, 446–450 (2000).
100. Ross JS, Figge HL, Bui HX et al. Ecadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage and clinical outcome. Mod. Pathol. 7, 835–841 (1994).
101. Sandberg AA. Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 23, 368–380 (1992).
102. Kallakury BV, Sheehan CE, Winn-Deen E., Harington KJ, Syrigos KN. The role of Ecadherin- catenin complex: more than an intercellular glue? Ann. Surg. Oncol. 7, 783–788 (2000).
103. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote -catenin nuclear translocation independently of APC. J. Biol. Chem. (2002).
104. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking -catenin to androgen signaling pathway. J. Biol. Chem. (2002)
105. Kallakury BVS, Yang F, Figge J et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy. Cancer 78, 1461–1469 (1996).
106. Cohen M.B., Griebling TL, Ahaghotu CA et al. Cellular adhesion molecules in urologic malignancies. Am. J. Clin. Pathol. 107 56–63 (1997).
107. Verkaik NS, van Steenbrugge GJ, van Weerden WM et al. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest. 80, 1291–1298 (2000).
108. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol. Pathol. 52, 189–196 (1999).
109. Pujol P, Maudelond T, Daures JP et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71, 2006–2012 (1993).
110. Makar R, Mason A, Kittleson JM et al. Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod. Pathol. 7, 747–751 (1994).
111. Ross JS, Nazeer T, Figge HL et al. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Am. J. Clin. Pathol. 104, 36–41 (1995).
112. McCabe NP, Angwafo FF, Zaher A et al. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol. Rep. 7, 879–882 (2000).
113. Peehl DM. Oncogenes in prostate cancer. Cancer 71, 1159–1164 (1993).
114. Wang YZ, Wong YC. Oncogenes and tumor suppressor genes in prostate cancer: a review. Urol. Oncol. 3, 41–46 (1997).
115. Neto GJ, Humphrey PA. Molecular biologic aspects of human prostatic carcinoma. Am. J. Clin. Pathol. 102 \(Suppl.1), S57–S64 (1994).
116. Ross JS, Fletcher JA. The HER-2/neu Oncogene in breast cancer: prognostic factor, predictive factor and target of therapy. Oncologist 3, 237–252 (1998).
117. Ross JS, Sheehan C, Hayner-Buchan A et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol. 28, 827–833 (1997).
118. Mark HF, Feldman D, Das S et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp. Mol. Pathol. 66, 170– 178 (1999).
119. Kaltz-Wittmer C, Klenk U, Glaessgen A et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Invest. 80, 1455–64 (2000).
120. Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59, 803–806 (1999).
121. Signoretti S, Montironi R, Manola J et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 92, 1918–1925 (2000).
122. Ross JS, Kallakury BVS, Figge J. Pathology and molecular biology of prostate cancer. In: Imaging of the Prostate. Rifkin MD (Ed.), Lippincott Raven Press, New York, NY, USA, (1997).
123. Kallakury BVS, Figge J, Ross JS et al. Association of p53 immunoreactivity with high Gleason grade in prostatic adenocarcinoma. Hum. Pathol. 25, 92–97 (1994).
124. Navone N, Troncoso P, Pisters L et al. p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl Cancer Inst. 85, 1657– 1669 (1993).
125. Stackhouse GB, Sesterhenn IA, Bauer JJ et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J. Urol. 162, 2040– 2045 (1999).
126. Leibovich BC, Cheng L, Weaver AL et al.
127. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J. Urol. 164, 716–721 (2000).
128. Quinn DJ, Henshall SM, Head DR et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 60, 1585–1594 (2000).
129. Visakorpi T, Kallioniemi O-P, Heikkinen A et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl Cancer Inst. 84, 883–887 (1991).
130. Chi SG, de Vere White RW, Meyers FJ et al. p53 in prostate cancer: frequent expressed transition mutations. J. Natl Cancer Inst. 86, 926–933. (1994)
131. Kallakury BVS, Jennings TA, Ross JS et al. Alteration of the p53 gene locus in benign hyperplastic prostatic epithelium associated with high grade prostatic adenocarcinoma. Diag. Mol. Pathol. 3, 227–232 (1994).
132. Meyers FJ, Chi SG, Fishman JR et al. p53 mutations in benign prostatic hyperplasia. J. Natl Cancer Inst. 85, 1856–1858 (1993).
133. Graff JR, Konicek BW, McNulty AM et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275, 24500– 24505 (2000).
134. McMenamin ME, Soung P, Perera S et al. Loss of PTEN expression in paraffinembedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291–4296 (1999).
135. Heidenreich B, Heidenreich A, Sesterhenn A et al. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur. Urol. 38, 475–482 (2000).
136. Nguyen TT, Nguyen CT, Gonzales FA et al. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate 15 43, 233–242 (2000).
137. Dong JT, Rinker-Schaeffer CW, Ichikawa T et al. Prostate cancer-biology of metastasis and its clinical implications. World J. Urol. 14, 182–189 (1996).
138. Brewster SF, Browne S, Brown KW. Somatic allelic loss at the DCC, APC, nm23 H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J. Urol. 151, 1073–1077 (1994).
139. Bhangal G, Halford S, Wang J et al. Expression of the multi-drug resistance gene in human prostate cancer. Urol. Oncol. 5, 118–121 (2000).
140. Lee W-H, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the -class glutathione-Stransferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 1733–1737 (1994).
141. Cookson MS, Reuter VE, Linkov I et al. Glutathione-S-transferase (GST-) class expression by immunohistochemistry in benign and malignant prostate tissue. J. Urol. 157, 673–676 (1997).
142. Suh CI, Shanafelt T, May DJ et al. Comparison of telomerase activity and GST- promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol. Cell Probes 14, 211–217 (2000).
143. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res. 301, 153–162 (2000).
144. Krajewski S, Bodrug S, Krajewska M et al. Immunohistochemical analysis of McL-1 protein in human tissues. Differential regulation of McL-1 and bcl-2 protein production suggests a unique role for McL-1 in control of programmed cell death in vivo. Am J Pathol 146, 1309–1319 (1995).
145. Shabaik AS, Krajewski S, Burgan A et al. bcl-2 protooncogene expression in normal, hyperplastic and neoplastic prostate tissue. J. Urol. Pathol. 3, 17–27 (1995).
146. Kallakury BVS, Figge J, Leibovich B et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod. Pathol. 9, 41–47 (1996).
147. Wymenga LF, Wisman GB, Veenstra R et al. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Urol. Oncol. 6, 57–62 (2001).
148. Wang Z, Ramin SA, Tsai C et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol. Oncol. 6, 57–62 (2001).
149. Finlay JA, Day JR, Evans CL et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin. Chem. 47, 1218–1224 (2001).
150. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279–284 (1999).
151. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker- Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59, 5483–5487 (1999).
152. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59, 5719–5723 (1999).
153. Razani B, Schlegel A, Liu J, Lisanti MP. Caveolin-1, a putative tumour suppressor gene. Biochem. Soc. Trans. 29 \(Pt 4), 494–499 (2001).
154. Li L, Yang G, Ebara S et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386–4392 (2001).
155. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46, 249–256 (2001).
156. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl Acad. Sci. USA 97, 3850–3855 (2000).
157. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 17, 337–344 (1999).
158. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615–2622 (1999).
159. Frankel A, Man S, Elliott P et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS- 341. Clin. Cancer Res. 6, 3719–3728 (2000).